Jupiter Asset Management Ltd. bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 20,831 shares of the biotechnology company’s stock, valued at approximately $3,845,000.
Several other institutional investors have also recently bought and sold shares of the company. Knott David M raised its stake in United Therapeutics by 5.5% during the 2nd quarter. Knott David M now owns 15,300 shares of the biotechnology company’s stock valued at $2,745,000 after acquiring an additional 800 shares during the last quarter. Origin Asset Management LLP raised its stake in shares of United Therapeutics by 6.4% during the 2nd quarter. Origin Asset Management LLP now owns 18,760 shares of the biotechnology company’s stock worth $3,366,000 after buying an additional 1,135 shares in the last quarter. Millennium Management LLC raised its stake in shares of United Therapeutics by 38.0% during the 2nd quarter. Millennium Management LLC now owns 553,139 shares of the biotechnology company’s stock worth $99,239,000 after buying an additional 152,287 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new position in shares of United Therapeutics during the 2nd quarter worth approximately $4,009,000. Finally, AlphaCrest Capital Management LLC purchased a new position in shares of United Therapeutics during the 2nd quarter worth approximately $1,133,000. 96.15% of the stock is owned by institutional investors and hedge funds.
UTHR opened at $213.96 on Friday. The stock has a market cap of $9.64 billion, a P/E ratio of 21.68, a P/E/G ratio of 13.69 and a beta of 0.57. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.46 and a quick ratio of 7.15. The stock’s 50 day simple moving average is $200.68 and its 200 day simple moving average is $196.99. United Therapeutics Co. has a 1-year low of $153.92 and a 1-year high of $218.38.
In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, December 2nd. The stock was sold at an average price of $189.36, for a total value of $1,136,160.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Christopher Patusky sold 2,300 shares of the firm’s stock in a transaction dated Monday, November 8th. The shares were sold at an average price of $200.16, for a total value of $460,368.00. The disclosure for this sale can be found here. Insiders sold a total of 63,126 shares of company stock worth $12,541,726 over the last ninety days. Corporate insiders own 12.10% of the company’s stock.
About United Therapeutics
United Therapeutics Corp. operates as a biotechnology company which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
Featured Story: Dividend Stocks – Are They Right For You?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.